论文部分内容阅读
目的探讨血清胸苷激酶1(TK-1)在恶性肿瘤疗效评估中的价值。方法采用增强化学发光法检测39例恶性肿瘤患者化疗过程中101人次的血清TK-1水平,并结合其他肿瘤标志物和实体瘤疗效评价标准(RECIST)进行疗效综合评估。结果Ⅱ期肿瘤患者组血清TK-1水平高于Ⅳ期患者组[(2.37±2.59)pmol/L vs.(1.11±0.77)pmol/L](P<0.05)。血清TK-1与RECIST诊断符合率为71.8%,高于其他肿瘤标志物与RECIST诊断符合率(P<0.05)。结论血清TK-1是评估恶性肿瘤疗效和预后的有效标志物。
Objective To investigate the value of serum thymidine kinase 1 (TK-1) in evaluating the efficacy of malignant tumors. Methods The level of serum TK-1 in 101 patients with malignant tumor during chemotherapy was detected by enhanced chemiluminescence. Combined with other tumor markers and RECIST, the therapeutic effect was evaluated. Results The level of serum TK-1 in patients with stage II tumor was significantly higher than that in patients with stage IV [(2.37 ± 2.59) pmol / L vs. (1.11 ± 0.77) pmol / L], respectively (P <0.05). The coincidence rate of serum TK-1 and RECIST was 71.8%, which was higher than that of other tumor markers and RECIST (P <0.05). Conclusion Serum TK-1 is a useful marker to evaluate the efficacy and prognosis of malignant tumors.